chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Had PROQUAD squirted in to his eye while the nurse was attempting to administered the PROQUAD to different seperate person; No adverse affects; This spontaneous report was received from a nurse regarding a male patient of unknown age. The patient's concomitant therapies included sterile diluent. The patient's pertinent medical history, drug reaction and drug allergies were unknown. On an unknown date, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) Lot# T7E48 and expiry date: 20-JUN-2020 (strength, dose, route not reported) for prophylaxis. On an unknown date, the patient had exposed with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) in to his eye while the nurse was attempting to administer the measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) to a separate person because they jerked while receiving vaccine (accidental exposure to product). No adverse affects reported (no adverse event).  This case is one of the several reports from the same reporter.
Fever, chills, headache, bodyache (muscle sore) under armpit very painful.
Systemic: Abdominal Pain-Mild, Systemic: Dizziness / Lightheadness-Mild, Systemic: Nausea-Mild, Systemic: Vomiting-Mild, Additional Details: vomit x1
headache; body aches; nausea; shooting pain through back; 101.1 fever; chills; Sore arm; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  An adult female patient (unknown if pregnant) received bnt162b2 (BNT162B2), on 17Oct2021 as dose 3 (booster), single (Lot number: FH8027) at the age of 36 years, in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: ELINEST taken for contraception (ongoing). Vaccination history included: bnt162b2 (Dose 1, Lot number: EK9231, Time: 13:00, Vaccination site: left arm upper), administration date: 30Dec2020, when the patient was 35-year-old, for COVID-19 immunisation, reaction(s): "headache", "Sore arm"; bnt162b2 (Dose 2, Lot number: EL8982, Time: 13:00, Vaccination site: left arm upper), administration date: 20Jan2021, when the patient was 35-year-old, for COVID-19 immunisation, reaction(s): "Headache", "Body aches", "Sore arm", "nause", "Slight fever". The following information was reported: HEADACHE (non-serious), outcome "unknown"; PAIN (non-serious), outcome "unknown", described as "body aches"; NAUSEA (non-serious), outcome "unknown"; BACK PAIN (non-serious), outcome "unknown", described as "shooting pain through back"; PYREXIA (non-serious), outcome "unknown", described as "101.1 fever"; CHILLS (non-serious), outcome "unknown"; PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "Sore arm". Relevant laboratory tests and procedures are available in the appropriate section.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201152033 same patient and reporter, different dose and event;
MODERATE-SEVERE PAIN  AT INJECTION SITE AND RADIATING DOWN SAME ARM. HEADACHE. TIREDNESS. BODY ACHES.
Patient was given DTaP instead of TdaP. He is 13 years old. Per CDC, it does count as valid dose. May have more of a injection site reaction.
shingles/herpes zoster-viral infection of the periocular and facial region; cornea keratitis herpes zoster; postherpetic polyneuropathy; Information has been received from a lawyer regarding a case in litigation which referred to a patient (pt) of unknown gender and age. Information regarding concomitant medications, concurrent conditions or medical history was not provided. On 28-JUN-2017, the pt was vaccinated with zoster vaccine live (ZOSTAVAX) for its intended purpose: the prevention of shingles (herpes zoster) and for routine health maintenance (exact dose, dose number, route of administration, anatomical site of vaccination, lot number and expiration date were not provided). Afterwards, on an unknown date (reported as shortly after receiving zoster vaccine live (ZOSTAVAX) vaccine), the pt suffered recurrent rash on the side of her head, face, hair line, nose and eye, accompanied by extreme pain on the right sde of head, scalp, and eye, and blurred vision. The pt was diagnosed with Herpes Zoster-viral infection of the periocular and facial region and shingles (herpes zoster), cornea keratitis herpes zoster (ophthalmic herpes zoster), and postherpetic polyneuropathy (post herpetic neuralgia). As a direct and proximate result of zoster vaccine live (ZOSTAVAX) vaccine, the pt sustained severe and permanent personal injuries; the pt's symptoms had resulted in physical limitations not present prior to using zoster vaccine live (ZOSTAVAX). The pt also experienced mental and emotional distress due to resulting physical limitations and seriousness of pt's condition. Further, the pt had suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. Finally, as direct and proximate result of zoster vaccine live (ZOSTAVAX), the pt had suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the events was considered as not recovered. The causal relationship between the events and zoster vaccine live (ZOSTAVAX) was assessed as related.  Herpes zoster, post herpetic neuralgia and ophthalmic herpes zoster were considered as disabling events by the reporter.   Upon internal review, the event ophthalmic herpes zoster was determined to be medically significant.
A non-serious spontaneous report of administration to a 51-year-old was received from a registered nurse concerning a 51-year-old adult patient. Neither medical history nor concomitant medications was reported for this patient. On 06-Nov-2009, the patient received H1N1, Intranasal vaccine for an unknown indication. There was no adverse event associated with this vaccination error; therefore, treatment and reporter causality assessments are not applicable, and the event is considered resolved.
3 inch x 6 inch local reaction around injection site (redness, swelling, pain).
On the same day of vax, the pt experienced redness and heat at the injection site, which was 1/2/ the size of a softball. Outcome: resolved. The most recent information received on 3/27/00 reports the condition of the pt as resolved.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. On 16-FEB-2013 ZOSTAVAX (lot # H0111048/expiry date 09-MAY-2013) was reconstituted with expired sterile diluent (lot # E010687/expiry date February 2012) (subcutaneous) and administered to the patient. Dose and dose number were not reported. No adverse symptoms were reported. This case is linked to cases MARRS#: 1303USA003573, 1303USA003574, 1303USA003575 and 1303USA003576 (same reporter link). Additional information has been requested.
Information has been received from a medical assistant referring to an adolescent patient of unknown age and gender. Concurrent conditions, medical history and concomitant medications were not reported. On 10-DEC-2015, the patient was vaccinated with second dose of improperly stored VAQTA, lot # L028666; expiry date 04-NOV-2016, (dose, route and frequency unspecified). No adverse effect was reported. This is one of several reports received from the same source. Additional information has been requested.
This spontaneous report was received from a registered nurse refers to a patient of unknown age who on 27-NOV-2012 was vaccinated with an improperly stored PROQUAD (dose and route unknown, Lot #: H015623, Exp date: 21-FEB-2014. No other co-suspects were reported. No concomitant medications were reported. No adverse event reported. Patient's outcome was unknown. This is one of several reports from the same source. Additional information is not expected.
Menstrual cycle is 7 days late post vaccine. Tested negative for pregnancy. Cycle is Normal at 26-27 days and currently on day 33 with no period.
The patient received 1st dose, about 2 minutes after felt dizzy then fainted. The patient was accompanied by mother and grandmother. He passed out for several seconds then came back and said he felt hot, fingers on right hand felt tingling. Looked like he might have passed out again but for only 1 second. My mom requested EMTs be called, EMTs called and patient taken by ambulance to hopital. Mother did call 2 hours later saying the patient was released and doing fine.
Patient reported a low grade fever and face/tongue numbness beginning 1 hour post-vaccination. She reported no difficulty breathing, but noted that eating and drinking was bothersome. No swelling/redness. Referred to the local urgent care for follow up.
rash covering most of my upper left arm, 2 small dots at injection site rash was ichy and burning,  about a 6 on a scale of 1-10
12 hours post dose 2 covid vaccine, patient had high heart rate to 160 and temp of 101 and diaphoresis
Headache and dizziness on 6/16/2021, went to the emergency room, and was found to have cerebral venous sinus thrombosis. His second vaccine was done on 5/12/2021.
rash occurred by 4PM from head to toe; fever 102 or 3 given APAP 4PM; wen to ER @ 10PM-very fussy-inconsolable for 2 hrs-1/2 hr sleep; when awoke unconsolable again until MN or later;
Information has been received from the VAERS database via a journalist. This spontaneous report refers to a patient of unknown age. The patient was vaccinated with lot # (658208/0886U) ZOSTAVAX on 17-SEP-2007. No other co-suspects were reported. No concomitant medications were reported. On an unknown date the patient experienced herpes zoster. No treatment information was reported. The outcome of herpes zoster is unknown. The relatedness for herpes zoster is unknown for ZOSTAVAX. Additional information is not expected.
Case number PHEH2017US005319, is an initial spontaneous report received from a consumer on 18 Feb 2017. This report refers to a 56 years old female patient. Past medical history and concomitant medications were not reported. The patient was vaccinated with single dose of FLUCELVAX QUADRIVALENT (batch number: not reported) at a dose of 0.5 ml, intramuscularly on an unspecified date in Nov 2016. On 13 Feb 2017, the patient experienced sore throat, laryngitis, body aches and difficulty breathing. On 18 Feb 2017, the patient was diagnosed with influenza type A. The patient received treatment with liquid lidocaine for sore throat. The patient visited emergency room (urgent care). The outcome of influenza type A was not reported and rest of all events was reported as condition improving. The seriousness of the event influenza type A was not reported and rest of all events was reported as non serious. The causality of the events was not reported. The seriousness assessment of influenza, vaccination failure was upgraded to serious (medically significant) based on the information available in the source document.
Within minutes patient experienced  light headedness, flushing, reports that he felt like fainting and he felt his heart racing He was taken to ER and only finding was elevated BP.  Pt was interviewed an hour after incident and reported that all sx had resolved.  Pt was discharged and came by vaccine clinic to report he had recovered.
Case number PHEH2015US023915 is an initial spontaneous report from a health care professional received on 12 Nov 2015. This report refers to a patient of an unknown age and gender. The patient was vaccinated with FLUVIRIN (batch number: not reported) intramuscularly on an unknown date. It was reported that while receiving the vaccine, little amount of it squinted on the face of the patient. No adverse event reported following this medication error.
Maculopapular rash-small, evenly distributed erythematous macules (slightly raised but smooth), does not blanch
This spontaneous report as received from a health professional refers to unspecified number of children patients of unknown age. On an unknown date, the patients were vaccinated with M-M-R II for prophylaxis. On an unknown date the patients experienced measles antibody negative, mumps antibody test negative and rubella antibody negative. The outcome of measles antibody negative, mumps antibody test negative and rubella antibody negative is unknown. The nurse could not confirm whether or not these patients had received any doses of M-M-R II prior to be tested for immunity. Sender's Comments: US-009507513-1708USA009503: US-009507513-1708USA010123: US-009507513-1708USA009693.
Fever, headache, chills, muscle aches, swollen arm at site, lightheadedness
hives on her ears and cheeks; it is very itchy; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (hives on her ears and cheeks) and PRURITUS (it is very itchy) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L2O4) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Mar-2021, the patient experienced URTICARIA (hives on her ears and cheeks) and PRURITUS (it is very itchy). At the time of the report, URTICARIA (hives on her ears and cheeks) and PRURITUS (it is very itchy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Reportedly, the patient is taking unspecified concomitant medications.  The patient did not receive any treatment for these events.  However, the patient wanted to know if she could take Benadryl (diphenhydramine).
This spontaneous report as received from a pharmacist refers to a 64 year old female patient. The pharmacist reproted that on, 26-JAN-2015 (reported as "today"), the patient was vaccinated with expired dose of PNEUMOVAX 23 lot # J010332, expiration date: 14-JAN-2015, 0.5 ml, intramuscular in the left deltoid. No adverse effects were reported. Additional information is not expected because the reporter did not wish to be contacted.
After 24hrs, flu-like symptoms, head and neck aches, chills with fever, nausea, large red swelling where shot was given. Fatigue the next day. Light headed.
receiving doses from vials affected by a temperature excursion; receiving doses from vials affected by a temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (receiving doses from vials affected by a temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (receiving doses from vials affected by a temperature excursion) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 049l21a) for COVID-19 prophylaxis.     No Medical History information was reported.    On 06-Jul-2022 at 1:30 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Jul-2022 at 1:30 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (receiving doses from vials affected by a temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (receiving doses from vials affected by a temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (receiving doses from vials affected by a temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (receiving doses from vials affected by a temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not reported.  Patient received doses from the lot number 049l21a affected by a temperature excursion as their freezer went out of range. Patient received half dose. It was reported that no adverse event occurred at time of administration or were reported thereafter.  Treatment medications were not reported.
fever 100.3 & 101.6, chills & body aches. Next day symptoms were gone.
This spontaneous report as received from a Registered Nurse refers to a patient of unknown age and gender. Concurrent conditions and other medical history were not reported. The nurse reported that on 22-JUL-2015, the patient was inadvertently vaccinated with a dose of (Oka/Merck) VARIVAX Subcutaneous injection (0.5 mL, subcutaneously, lot # K003411, expiration date 06-MAR-2015), instead of the intended dose of ZOSTAVAX. No adverse experience was reported. Additional information has been requested.
On 04/04/2021 after having memory issues I went to the emergency room and was diagnosed as having 3 strokes.  I woke up with a throbbing headache and then had difficultly remembering simple things like using the remote control for TV. My vision was also somewhat blurry. I then went to drive and my focus was off making driving difficult so I then went to the emergency room
Received second dose Pfizer shot on November 5, 2021. Five minutes after receiving the dose I fainted in the waiting room. Nurses came and had high blood pressure and heart rate. Reminder that I was 24 years old at the time and very active and fit. Within two months after receiving the second dose, I developed several neurological issues such as brain fog and intense anxiety, along with tingling in my hands and feet. I also developed severe chest pain and intense pain in my spine making even sitting up a struggle. I have been to several doctors and have had numerous of tests done which all come back normal and cannot explain any of the systems that I have been experiencing for over a year now.
Patient called pharmacy on 8/28/17 and reported: "The day after I got the shots, I came down with the flu...The skin around the injections is red, tender, and a little swollen...The swollen red area is about the size of 1/3 a sheet of paper. The swelling/redness was the worst the day after the shots, and has been improving since, but is still the majority of my upper arm." Upon questioning, patient clarified "coming down with the flu" as muscle aches, fatigue, and general malaise. I explained that these reactions, while severe, were within the normal spectrum of expected AEs. Recommended the use of an OTC pain reliever for arm soreness and instructed patient to contact us again if symptoms worsened or if the swelling and erythema didn't continue to improve. I called and left a voicemail for the patient at 2:24pm on 8/29/17 requesting a follow-up, but have not heard back.
Started itching and my head felt woozy and swimmy.  I felt like I couldn't put words together.  I also started to itch all over my face, head and body.  My neck started to get stiff.
Redness or blush on left arm and hand up to elbow; Redness or blush on left arm and hand up to elbow; This is a spontaneous report from a contactable consumer (patient). An 83-year-old female patient received first dose of bnt162b2 (Pfizer COVID19 Vaccination, solution for injection, Batch/lot number: EN6207, Expiry date: 31Jul2021), via an unspecified route in the left arm on 21Mar2021 at 10:30 in the morning (age at vaccination: 83-year-old), as a single dose for covid-19 immunization. Medical history included AFib (atrial fibrillation) in 2018 ongoing, ongoing hypertension from long time ago and it has been 11 years since she smoked/ex-smoker ongoing. Patient has six medications she takes (not reported). Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 21Mar2021 at 15:30, patient experienced redness or blush on left arm and hand up to elbow/ redness/pinkish was mostly on her hand and went up to wrist and a little up to the elbow. Today (22Mar2021) it is very slight but is still there. Adverse events did not result in emergency room or physician office visit. The clinical outcome of the events recovering/resolving.  No follow-up attempts are possible. No further information is expected.
Right hand "froze up." Was painful. Could move tips of fingers a bit but very difficult to grasp. Right wrist became swollen and had a rash.
upper arm aching & weak; cannot lift as much as usual in certain positions; It still hurts three months p/shot;
Patient received expired vaccine; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received expired vaccine) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001C21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received expired vaccine). On 14-Oct-2021, EXPIRED PRODUCT ADMINISTERED (Patient received expired vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   07Oct2021: Removed from freezer & placed in the refrigerator. 14Oct2021: Administered to 21 patients/soldiers.  Concomitant medications was not provided by the reporter Treatment information was not provided
This spontaneous case was reported by a patient (subsequently medically confirmed) and describes the occurrence of MYOCARDIAL INFARCTION (Myocardial infarction) and CHEST PAIN (Pain in the chest) in a 64-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 002B21A and 040A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below. Concurrent medical conditions included Penicillin allergy. Concomitant products included LISINOPRIL and ATORVASTATIN. On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 12-Apr-2021, the patient experienced MYOCARDIAL INFARCTION (Myocardial infarction) (seriousness criteria medically significant and life threatening), CHEST PAIN (Pain in the chest) (seriousness criterion life threatening), LETHARGY (Lethargic), DYSPEPSIA (Heart ache) and FATIGUE (Tired). On an unknown date, the patient experienced HEADACHE (Headache). On 14-Apr-2021, MYOCARDIAL INFARCTION (Myocardial infarction) and CHEST PAIN (Pain in the chest) outcome was unknown. At the time of the report, LETHARGY (Lethargic) and FATIGUE (Tired) had not resolved, DYSPEPSIA (Heart ache) was resolving and HEADACHE (Headache) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In April 2021, Electrocardiogram: abnormal Showed mild Heart Attack. His doctor gave him nitroglycerin which he could not take due to headache and full aspirin. His cardiologist appointment is coming up on 25MAY2021. Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.  Further information has been requested. This case was linked to MOD-2021-114362 (Patient Link).; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.  Further information has been requested.